Loading...

Brilliant Violet 510™ anti-human CD19 Antibody

Pricing & Availability
Clone
HIB19 (See other available formats)
Regulatory Status
RUO
Workshop
V CD19.11
Other Names
B4
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
HIB19_BV510_CD19_Antibody_FC_082512
Human peripheral blood lymphocytes were stained with CD3 APC and CD19 (clone HIB19) Brilliant Violet 510™.
  • HIB19_BV510_CD19_Antibody_FC_082512
    Human peripheral blood lymphocytes were stained with CD3 APC and CD19 (clone HIB19) Brilliant Violet 510™.
See Brilliant Violet 510™ spectral data
Cat # Size Price Quantity Check Availability Save
302241 25 tests 146€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
302242 100 tests 313€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD19 is a 95 kD type I transmembrane glycoprotein also known as B4. It is a member of the immunoglobulin superfamily expressed on B-cells (from pro-B to blastoid B cells, absent on plasma cells) and follicular dendritic cells. CD19 is involved in B cell development, activation, and differentiation. CD19 forms a complex with CD21 (CR2) and CD81 (TAPA-1), and functions as a BCR co-receptor.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections8 and blocking of B cell proliferation. Clone HIB19 is not recommended for formalin-fixed paraffin-embedded sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 302267 & 302268).

 

Clone HIB19 partially blocks anti-human CD19 clones 4G7 and SJ25C1 staining based on in-house testing

Application References
  1. Schlossman S, et al. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  3. Bradbury L, et al. 1993. J. Immunol. 151:2915.
  4. Joseph A, et al. 2010. J. Virol. 84:6645. PubMed
  5. Wang X, et al. 2010. Haematologica. 95:884. (FC) PubMed
  6. Walker JD, et al. 2009. J. Immunol. 182:1548. (Block) PubMed
  7. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  8. Hansen A, et al. 2002. Arthritis Rheum. 46:2160. (IHC)
  9. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
  10. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
Product Citations
  1. Rutishauser L, et al. 2017. AIDS Res Hum Retroviruses . 10.1089/AID.2016.0324. PubMed
  2. Martrus G, et al. 2017. PLoS One.. 10.1371/journal.pone.0182532. PubMed
  3. Bradley T et al. 2018. Cell. 175(2):387-399 . PubMed
  4. Lagou V et al. 2018. Cell reports. 25(3):798-810 . PubMed
  5. Sagebiel AF, et al. 2019. Nat Commun. 10:975. PubMed
  6. Baxter AE, et al. 2017. Nat Protoc. 12:2029. PubMed
  7. Ruella M, et al. 2018. Nat Med. 24:1499. PubMed
  8. Shih T, et al. 2019. Front Immunol. 10:1652. PubMed
  9. Abd Hamid M et al. 2019. Cancer Immunol Res. 7(8):1293-1306 . PubMed
  10. Moguche AO et al. 2017. Cell host & microbe. 21(6):695-706 . PubMed
  11. Upasani V, et al. 2019. Front Immunol. 2.152777778. PubMed
  12. Weisberg SP, et al. 2020. Cell Reports. 29(12):3916-3932.e5.. PubMed
  13. Catapano M, et al. 2020. J Invest Dermatol. 140:816. PubMed
  14. Krummey SM, et al. 2020. Cell Reports. 30(5):1282-1291.e5.. PubMed
  15. Giron LB, et al. 2020. EBioMedicine. 73.94791667. PubMed
  16. Pucino V, et al. 2020. Cell Metabolism. 30(6):1055-1074.e8.. PubMed
  17. Morris AB, et al. 2020. Immunity. 52(1):136-150.e6.. PubMed
  18. Sekine T, et al. 2020. Cell. 183:158. PubMed
  19. Sung JA, et al. 2018. Mol Ther. 26:2496. PubMed
  20. Demers K, et al. 2016. PLoS Pathog. 12: 1005805. PubMed
  21. Mackroth M, et al. 2016. PLoS Pathog. 12:e1005909. PubMed
  22. Rakshit S, et al. 2020. Cell Rep. 33:108451. PubMed
  23. Bäcker-Koduah P, et al. 2020. Ann Clin Transl Neurol. 1.422222222. PubMed
  24. Danzer H, et al. 2020. Elife. 9:00. PubMed
  25. Hu EY, et al. 2020. JCI Insight. 5:00. PubMed
  26. Eslamizar L, et al. 2021. NPJ Vaccines. 6:15. PubMed
  27. Buggert M, et al. 2020. Cell. 183(7):1946-1961.e15. PubMed
  28. Bonifacius A, et al. 2021. Immunity. 54(2):340-354.e6. PubMed
  29. Caduff N, et al. 2021. Cell Reports. 35(5):109056. PubMed
  30. Tong P, et al. 2021. Cell. :. PubMed
  31. Sannier G, et al. 2021. Cell Reports. 36(9):109643. PubMed
  32. Chen Y, et al. 2020. Cell. 1496:183. PubMed
  33. Vanderbeke L, et al. 2021. Nat Commun. 12:4117. PubMed
  34. Cohen CA, et al. 2021. Nat Commun. 12:4678. PubMed
  35. Kuri-Cervantes L, et al. 2020. STAR Protoc. 1:100154. PubMed
  36. Hu EY, et al. 2021. Blood Adv. 5:3152. PubMed
  37. Pape KA, et al. 2021. Cell Rep. 37:109823. PubMed
  38. Gamradt S, et al. 2021. iScience. 24:103312. PubMed
  39. Chen M, et al. 2021. Cancers (Basel). 13:. PubMed
  40. Kokkinopoulos I, et al. 2021. Sci Rep. 11:15759. PubMed
  41. Yarmarkovich M, et al. 2021. Nature. 599:477. PubMed
  42. Romero-Olmedo AJ, et al. 2022. Nat Microbiol. 7:195. PubMed
  43. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  44. NULL, et al. 2022. Cell. 185:916. PubMed
  45. van der Ploeg K, et al. 2022. Cell Rep Med. 3:100640. PubMed
  46. Groß R, et al. 2022. EBioMedicine. 75:103761. PubMed
  47. Pape KA, et al. 2022. JCI Insight. 7:. PubMed
  48. Peluso MJ, et al. 2021. Cell Rep. 36:109518. PubMed
  49. Li C, et al. 2022. J Exp Med. 219:. PubMed
  50. Schlicher L, et al. 2022. Int J Mol Sci. 23:. PubMed
  51. Gao Y, et al. 2022. Immunity. 55:1732. PubMed
  52. Silver J, et al. 2020. Methods Mol Biol. 2121:115. PubMed
  53. Kim JH, et al. 2020. Sci Rep. 10:1835. PubMed
  54. Chen Y, et al. 2022. Sci Immunol. 7:eabp8328. PubMed
  55. McEvoy CM, et al. 2022. Nat Commun. 13:7634. PubMed
  56. Touizer E, et al. 2023. iScience. 26:105862. PubMed
  57. Musvosvi M, et al. 2023. Nat Med. 29:258. PubMed
  58. Collora JA, et al. 2022. Immunity. 55:1013. PubMed
  59. Parry H, et al. 2022. Cell Rep Med. 3:100739. PubMed
  60. Adamo S, et al. 2023. Cell Host Microbe. 31:928. PubMed
RRID
AB_2561381 (BioLegend Cat. No. 302241)
AB_2561668 (BioLegend Cat. No. 302242)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 95 kD
Distribution

B lineage (except plasma cells), follicular dendritic cells

Function
B cell activation and differentiation
Ligand/Receptor
Forms complex with CD21 (CR2) and CD81 (TAPA-1), BCR coreceptor
Cell Type
B cells, Dendritic cells
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Tedder T, et al. 1994. Immunol. Today 15:437.
2. Bradbury L, et al. 1993. J. Immunol. 151:2915.

Gene ID
930 View all products for this Gene ID
UniProt
View information about CD19 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 2    Revision Date: 12/18/2013

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account